IP Library › Granted Patent US 12,227,497
Granted Patent B2
US 12,227,497 · App. 17/978,848 · Granted Feb 18, 2025

Solid forms of(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Inventor: Antonio J. Barbosa (Ave Maria, FL)
Assignee: ATEGRIN, INC.
C07D417/06A61P35/00C07C215/08C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,497
App. No.
17/978,848
Granted
Feb 18, 2025
Kind
B2
Abstract

The present invention provides new salts and crystalline forms of leukadherin LA1 [(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid] according to Formula I. Methods for preparation of the salts and crystalline forms are also described, as well as methods for treating β2 integrin-mediated diseases and conditions using the salts and crystalline forms.

Claims (11)

1. A method for treating an autoimmune or inflammatory disease, the method comprising: administering to a patient having an autoimmune or inflammatory disease a choline salt or a meglumine salt of a compound according to Formula (I)

or a crystalline form thereof.

2. The method of claim 1 , wherein the salt is a choline salt according to Formula (I) or a crystalline form thereof.

3. The method of claim 1 , wherein the is a meglumine salt according to Formula (I) or a crystalline form thereof.

4. The method of claim 1 , wherein the autoimmune or inflammatory disease is a member selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease, lupus, lupus nephritis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

5. The method of claim 1 , wherein the autoimmune or inflammatory disease is lupus or lupus nephritis.

6. The method of claim 1 , wherein the autoimmune or inflammatory disease is a member selected from multiple sclerosis, Alzheimer's disease, and Parkinson's disease.

7. The method of claim 1 , wherein the compound of Formula is in association with a carrier to form a pharmaceutical composition.

8. The method of claim 7 , wherein the pharmaceutical composition is a member selected from the group consisting of tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, elixirs, solutions, buccal patches, oral gels, chewing gums, chewable tablets, effervescent powders, and effervescent tablets.

9. The method of claim 8 , wherein the pharmaceutical composition is a tablet.

10. The method of claim 9 , wherein the tablet is uncoated or coated.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Mar 20, 2023
From: GB006, INC.; ATEGRIN, INC.
To: ATEGRIN, INC.
Reel/Frame 063036/0897 →
Continuity (7)
Continuation 17703839 · Mar 24, 2022
Continuation 17387850 · Jul 28, 2021
Continuation 16675097 · Nov 5, 2019
Continuation 15735560
Provisional Application 62275655 · Jan 6, 2016
Provisional Application 62175066 · Jun 12, 2015
Related Publication 20230227443A1 · Jul 20, 2023
References Cited (39)
US 7718680B2 · Pellecchia et al. · 2010 [cited by applicant]
US 8268816B2 · Gupta et al. · 2012 [cited by applicant]
US 8846667B2 · Gupta et al. · 2014 [cited by applicant]
US 9023876B2 · Gupta · 2015 [cited by applicant]
US 9328105B2 · Gupta · 2016 [cited by applicant]
US 20040002526A1 · Klein et al. · 2004 [cited by applicant]
US 20050042213A1 · Gelder et al. · 2005 [cited by applicant]
US 20070072922A1 · Brook et al. · 2007 [cited by applicant]
US 20120010255A1 · Gupta · 2012 [cited by applicant]
US 20140303026A1 · Gupta et al. · 2014 [cited by applicant]
US 20160151336A1 · Gupta · 2016 [cited by applicant]
WO 2005016227A2 · 2005 [cited by applicant]
WO 2006024699A1 · 2006 [cited by applicant]
WO 2006066846A1 · 2006 [cited by applicant]
WO 2008005651A2 · 2008 [cited by applicant]
WO 2008082537A2 · 2008 [cited by applicant]
WO 2008091532A1 · 2008 [cited by applicant]
WO 2012005800A1 · 2012 [cited by applicant]
WO 2013159082A1 · 2013 [cited by applicant]
WO 2016201356A1 · 2016 [cited by applicant]
Grant & Hackh's Chemical Dictionary (5th Ed. 1987) at p. 148. [cited by examiner]
U.S. Appl. No. 15/735,560, “Non-Final Office Action”, Mar. 21, 2019, 13 pages (available in Patent Center). [cited by applicant]
EP 16808465.5 , “Extended European Search Report”, Oct. 30, 2018, 8 pages. [cited by applicant]
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19. [cited by applicant]
Bjorklund , “Stabilization of the Activated amβ2 Integrin by a Small Molecule Inhibits Leukocyte Migration and Recruitment”, Biochemistry, vol. 45, Issue 9, Mar. 7, 2006, pp. 2862-2871. [cited by applicant]
Celik et al., “Agonist Leukadherin-1 Increases Cd11b/CD18-Dependent Adhesion via Membrane Tethers”, Biophysical Journal, vol. 105, Issue 11, Dec. 3, 2013, pp. 2517-2527. [cited by applicant]
Faridi et al., “High-Throughput Screening Based Identification of Small Molecule Antagonists of Integrin CD11b/CD18 Ligand Binding”, Biochem. Biophys. Res. Commun., vol. 394, Issue 1, Mar. 26, 2010, pp. 194-199. [cited by applicant]
Faridi et al., “Identification of Novel Agonists of the Integrin CD11b/CD18”, Bioorganic & Medicinal Chemistry Letters , vol. 19, Issue 24, Dec. 15, 2009, pp. 6902-6906. [cited by applicant]
Faridi et al., “Small Molecule Agonists of Integrin CD11b/CD18 Do Not Induce Global Conformational Changes and Are Significantly Better Than Activating Antibodies in Reducing Vascular Injury”, Biochimicaet Biophysica Ac… [cited by applicant]
Horig et al., “From Bench to Clinic and Back: Perspective on the 1st IQPC Translational Research Conference”, Journal of Translational Medicine, vol. 2, No. 1, Dec. 2004, 8 pages. [cited by applicant]
Jagarapu et al., “Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats”, Am J Respir Cell Mol Biol., vol. 53, Issue 6, Dec. 2015, pp. 793-801. [cited by applicant]
Khan et al., “A Small Molecule B2 Integrin Agonist Improves Chronic Kidney Allograft Survival by Reducing Leukocyte Recruitment and Accompanying Vasculopathy”, Original Research in Medicine, vol. 1, Article 45, Nov. 201… [cited by applicant]
Maiguel et al., “Small Molecule-Mediated Activation of the Integrin CD11b/CD18 Reduces Inflammatory Disease”, Science Signaling, vol. 4, No. 189, Sep. 6, 2011, pp. 1-32. [cited by applicant]
Park et al., “A Simple, No-Wash Cell Adhesion-Based High-Throughput Assay for the Discovery of Small-Molecule Regulators of the Lntegrin CD11b/CD18”, Journal of Biomolecular Screening, vol. 12, Issue 3, Apr. 2007, pp. 4… [cited by applicant]
PCT/US2016/037067 , “International Search Report and Written Opinion”, Sep. 8, 2016, 7 pages. [cited by applicant]
Reed et al., “Complement Receptor 3 Influences Toll-like Receptor 7/8-Dependent Inflammation”, The Journal of Biological Chemistry, vol. 288, Issue No. 13, Mar. 29, 2013, pp. 9077-9083. [cited by applicant]
Schafer et al., “Failure is an Option: Learning From Unsuccessful Proof-of-concept Trials”, Drug Discovery Today, vol. 13, Nos. 21-22, Nov. 2008, pp. 913-916. [cited by applicant]
Appln. BR112017026406-4, Written Opinion (office action), Apr. 2, 2024, 25 pages (with English translation). [cited by applicant]
Appln. BR122023025347-7, Written Opinion (office action), Apr. 2, 2024, 16 pages (with English translation). [cited by applicant]